Astec LifeSciences Limited submitted a formal response to BSE Limited regarding a significant increase in trading volume of the company's securities across exchanges in the recent past. The communication was issued in response to BSE's email reference number L/SURV/ONL/PV/SG/2026-2027/368 dated 18th September, 2026.
The company confirmed its awareness of responsibility to disseminate information that could impact share prices to stock exchanges. They stated consistent compliance with prompt disclosure requirements under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Key confirmations provided:
- Full compliance with disclosure requirements under Listing Regulations
- No developments requiring mandatory disclosure under Listing Regulations
- No developments requiring disclosure under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015
- Commitment to continue full compliance with disclosure obligations under both sets of regulations
The response was digitally signed by Tejashree Rohan Pradhan, Company Secretary & Compliance Officer (FCS 7167), on 18th September, 2026 at 15:25:51 IST. The company requested BSE to take this information on record.
No specific financial impact, operational developments, or material events were disclosed in this compliance response.